HEALTHWATCH INC
10KSB40, EX-10.7, 2000-09-28
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Previous: HEALTHWATCH INC, 10KSB40, EX-10.6, 2000-09-28
Next: HEALTHWATCH INC, 10KSB40, EX-21, 2000-09-28



<PAGE>

                                                                    Exhibit 10.7
Amendment to the Business Collaboration Agreement between HealthWatch, Inc. and
Halis, Inc.


                               AMENDMENT TO THE
                               -----------------
                       BUSINESS COLLABORATION AGREEMENT
                       --------------------------------

     This AMENDMENT TO THE BUSINESS COLLABORATION AGREEMENT ("Amendment"), dated
as of September 20, 2000 is made and entered into by and among (i) Halis, Inc.
("HALIS"), a Georgia corporation and (ii) HealthWatch, Inc. ("HealthWatch"), a
Minnesota corporation.

     WHEREAS, HALIS and HealthWatch have entered into that certain Business
Collaboration Agreement dated as of October 10, 1997 (the Agreement") to provide
both parties with access to the other party's software products; and

     WHEREAS, HALIS and HealthWatch both desire to extend the term of the
Agreement and adjust the royalty fees contained therein.

     THEREFORE, for good and valuable consideration, the receipt and sufficiency
of which hereby are acknowledged, the parties, intending to be legally bound, do
hereby agree as follows:

     1.  Section 2 of the Agreement shall be deleted in its entirety and
replaced with the following:

     "2.1  HealthWatch License. HALIS grants to HealthWatch a non-exclusive
           -------------------
     right to distribute, market, sub-license, and private label HALIS software
     products. HealthWatch agrees to pay HALIS, a $50,000 per month
     collaboration fee.  HealthWatch will share revenues received from such
     activities on a 60/40 basis, whereby 60% will be allocated to HealthWatch
     and 40% will be allocated to HALIS.  All collaboration fees paid to HALIS
     for the life of this agreement will be cumulated in the form of a credit to
     be applied to the revenue sharing amounts owed to HALIS by HealthWatch.
     Revenue sharing amounts will be determined on a quarterly basis, and any
     amount owed, net of the collaboration fee credits, will be paid to HALIS
     within 30 days after the conclusion of each quarter.  HALIS shall (i)
     provide support to HealthWatch for the HALIS software products and
     reasonable product enhancements as part of product release updates and (ii)
     accept and review input from HealthWatch with regard to reasonable product
     enhancement requests to be included in future product release updates.
     HealthWatch shall have the option to terminate its license granted under
     this Section 2.1 on or after October 1, 2001 upon 90 days prior written
     notice to Halis (provided all net revenue sharing fees are paid and
     current), in which event its obligation to pay the $50,000 monthly
     collaboration fee shall terminate.  Revenue sharing shall continue with
     respect to any sub-license previously granted by
<PAGE>

     HealthWatch under this Agreement. Previously paid collaboration fees shall
     continue to operate as a credit against amounts owed to HALIS. HALIS shall
     continue to provide support required under this Agreement for all
     outstanding product licenses issued by HealthWatch after such termination.
     However, should HealthWatch exercise its option to terminate the monthly
     collaboration fee, HALIS shall have the option to terminate its support
     obligations under this Section 2.1 in exchange for waiving all unearned
     future revenue sharing payments due to HALIS under this Section 2.1.

     2.2.  HALIS License. HealthWatch grants to HALIS a non-exclusive right to
           -------------
     market, distribute, sub-license and private label HealthWatch's information
     technology software. HALIS will share revenues received from such sales or
     sub-licensing of the HealthWatch software technology on a 60/40 basis,
     whereby 60% will be allocated to HALIS and 40% will be allocated to
     HealthWatch. The provisions of the Business Collaboration Agreement
     associated with this paragraph 2.2 will remain in effect for the term of
     the Agreement. All revenue sharing shall be paid to HealthWatch on a
     quarterly basis within 30 days after the conclusion of each quarter.


     2.3  Set-Offs Permitted.  HealthWatch and HALIS both agree that either
          ------------------
     party shall be permitted to deduct any amounts payable under this Agreement
     and apply such payment to any undisputed amounts due and payable from the
     other party as a result of fees payable under this Agreement, cost sharing
     arrangements between the parties or any other similar arrangements."


     2.  Section 6 of the Agreement shall be deleted in its entirety and
replaced with the following:

     "6.  Term.  The term of this Agreement shall expire on September 20, 2005,
          ----
     and shall be automatically extended for additional one-year terms, unless
     terminated by  one of the parties by giving a written notice to the other
     party ninety days prior to the end of the original term or the additional
     one year renewal terms."

     3.  Except as modified by this Amendment, all terms and conditions of the
Agreement are hereby reaffirmed.
<PAGE>

     IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the
effective date mentioned above.


HEALTHWATCH, INC.                               HALIS, INC.

/s/ David Engert                                /s/ Paul W. Harrison
----------------------------                    ----------------------------
By:  David Engert                               By: Paul W. Harrison
Its: Chief Operating Officer                    Its: President
Date: September 20, 2000                        Date: September 20, 2000


/s/ Tom Ridenour                                /s/ Joel Greenspan
----------------------------                    ----------------------------
By: Tom Ridenour                                By: Joel Greenspan
Its: Chief Financial Officer                    Its: Director
Date: September 20, 2000                        Date: September 20, 2000



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission